Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia

Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia

CD33 and CD123 are expressed on the surface of human acute myeloid leukemia blasts and other noncancerous tissues such as hematopoietic stem cells. On-target off-tumor toxicities may limit chimeric antigen receptor T cell therapies that target both CD33 and CD123. To overcome this limitation, we dev...

Full description

Bibliographic Details
Main Authors: Justin C. Boucher, Bishwas Shrestha, Paresh Vishwasrao, Mark Leick, Estelle V. Cervantes, Tayyebb Ghafoor, Kayla Reid, Kristen Spitler, Bin Yu, Brian C. Betts, Jose A. Guevara-Patino, Marcela V. Maus, Marco L. Davila
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Molecular Therapy: Oncolytics
Subjects:
CAR T
immunotherapy
AML
CD33
CD123
“AND” logic gate
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770523001006

Internet

http://www.sciencedirect.com/science/article/pii/S2372770523001006

Similar Items